Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
AHA 25: CRISPR-Cas9 Gene Editing Therapy Targeting ANGPTL3
Author(s): Stephen Nicholls Added: 1 day ago
AHA 2025 - Phase 1 results show the CRISPR-Cas9 gene editing therapy is a safe treatment option targeting ANGPTL3 in patients with lipid disorders.Prof Stephen Nicholls (Monash Victorian Heart Institute, Clayton, AU) joins us to share results from a first-in-human phase 1 trial investigating a one-time infusion of CTX310, a CRISPR-Cas9 gene editing therapy, at different doses targeting… View more

Prevention & Chronic Conditions
EASD 2025 Highlights: Updates on Icosapent Ethyl and Cardiometabolic Risk
Author(s): Rahul Aggarwal , Dirk Müller-Wieland Added: 1 month ago
Filmed onsite at EASD 2025, this on-demand series features key insights from Prof Dirk Müller-Wieland and Dr Rahul Aggarwal to interpret the latest data on eicosapentaenoic acid(EPA), including the latest sub-analysis of the REDUCE-IT trial, whichanalysed the effectiveness of icosapent ethyl (IPE) on CV risk by triglyceride-glucose (TyG) index - an indicator of insulin resistance and risk of type… View more

Heart Failure

Prevention & Chronic Conditions
REDUCE-IT: CV Outcomes With Icosapent Ethyl by Baseline LDL-C
Author(s): Deepak L Bhatt Added: 7 months ago
In this insightful interview, Dr Deepak Bhatt (Mount Sinai Hospital, US) joins us to discuss findings from a post-hoc analysis of the REDUCE-IT trial, examining how icosapent ethyl affects cardiovascular outcomes across different baseline LDL-C levels.The study included 8,175 statin-treated patients with elevated cardiovascular risk and triglyceride levels between 135-499mg/dL. All participants… View more

Prevention & Chronic Conditions
AHA Scientific Sessions 2025 Late-Breaking and Featured Science Collection
Author(s): Andrew Wang Added: 4 days ago
Stay at the forefront of cardiovascular medicine with our comprehensive video collection from the American Heart Association's Scientific Sessions 2025. Access expert analysis of the most impactful late-breaking trials and featured science shaping clinical practice.Late-Breaker Discussions: Watch Dr Harriette Van Spall break down pivotal clinical trial data and explore its implications for… View more

Cardiovascular Renal Metabolic

Heart Failure
ACC.24: Olezarsen for Hypertriglyceridemia and ASCVD
Author(s): Brian Bergmark Added: 1 year ago
ACC.24 — Dr Brian Bergmark (Brigham and Women's Hospital, Harvard Medical School, US) joins us in this interview to discuss the findings of a study into olezarsen, previously known as AKCEA-APOCIII-LRx, in patients with hypertriglyceridemia and atherosclerotic cardiovascular disease (ASCVD), with or without severe hypertriglyceridemia (NCT05355402).This multicenter, randomized, double-blind study… View more

Prevention & Chronic Conditions
Michael D Shapiro
Research Area(s) / Expertise: Job title: Director of the Center for Preventive Cardiology
Personal History Dr Shapiro lives in Winston-Salem with his wife and their two children. In his spare time, he enjoys travelling and hiking. Academic History Dr Shapiro completed medical school in 1998 at the UMDNJ School of Osteopathic Medicine. After completing a cardiology fellowship at the Beth Israel Medical Center, he spent two additional years in a clinical and research… View more
Secondary Prevention of Atherosclerotic Cardiovascular Disease
Author(s): Madelyn Hurwitz , Olayinka J Agboola , Abhishek Gami , et al Added: 6 months ago

Prevention & Chronic Conditions
Women As One CLIMB® 2024 Skills Training Program
Author(s): Victoria Delgado , Laura Sanchis , Julia Grapsa , et al Added: 9 months ago
About the CLIMB® Skills Training ProgramNow in its fifth year,the CLIMB program hasprovided free,advanced clinical skills training to over 390women physicians from 99 countries.This online program helps address the underrepresentation ofwomenin advanced procedural cardiology subspecialties.Physicians worldwide will now have on-demand access to didactic presentations delivered by leading faculty… View more

Demographic

Electrophysiology & Arrhythmia
ESC Congress 2025 Releases its Late-Breaking Scientific Programme
Added: 4 months ago Source:  ESC Congress 2025 Scientific Programme
ESC Congress 2025 has released twenty-eight late-breaking trials and science sessions to be presented in August 2025.The congress is set to take place from the 29th August to 1st September at IFEMA - Fiera de Madrid.Access the full programme here.Late-Breaking Clinical Science: Inflammation and Immune Biomarkers in Cardiovascular Risk PredictionFriday 29th August, 08:15am – 09:45am (CEST… View more

Cardiovascular Renal Metabolic

Demographic
HsCRP in ASCVD
Author(s): Adhya Mehta , Roger S Blumenthal , Ty J Gluckman , et al Added: 7 months ago

Prevention & Chronic Conditions